Clinical Trial Search

Phase 3 N=509 A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs

Rheumatoid Arthritis

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) C-Reactive Protein (CRP) Response at Week 12 — 30.7; 57.7; 74.5; 83.5 Percentage of…

Astellas Pharma Inc Results Mar 2020 4.8% serious AE View details

Phase 3 N=455 ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator

Helicobacter Pylori Infection · Dyspepsia

Primary: Number of Participants With Eradication of H. Pylori — 191; 131 Participants — p=0.0001

RedHill Biopharma Limited Results Mar 2020 0.4% serious AE View details

Phase 3 N=303 A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis

Axial Spondyloarthritis

Primary: Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response — 19.0; 35.4; 40.2 percentage of participants — p=0.009

Eli Lilly and Company Results Mar 2020 1.6% serious AE View details

Phase 3 N=382 A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — -1.0; 13.0 percentage points — p=<0.0001

Vertex Pharmaceuticals Incorporated Results Mar 2020 18.1% serious AE View details

Phase 3 N=763 Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Gastric Adenocarcinoma

Primary: Pembro Combo vs SOC: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review…

Merck Sharp & Dohme LLC Results Mar 2020 44.0% serious AE View details

Phase 3 N=68 Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization

COPD

Primary: Time to All-cause Mortality or Re-hospitalization During the 180 Days Post-randomization. — 54; 55 Days to event — p=<0.1

Temple University Results Mar 2020 45.3% serious AE View details

Phase 3 N=1,609 A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Diabetes · Diabetes Mellitus, Type 2

Primary: Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks) — 216.8; 243.9 Episodes/(PYE*100) — p=0.1715

Novo Nordisk A/S Results Mar 2020 19.3% serious AE View details

Phase 3 N=8,687 Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

Herpes Zoster

Primary: Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) — 5175; 963; 4422 Participants

GlaxoSmithKline Results Mar 2020 8.5% serious AE View details

Phase 3 N=1,091 Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -0.15; -0.09 Percentage of HbA1c — p=0.310

Novo Nordisk A/S Results Mar 2020 7.2% serious AE View details

Phase 3 N=299 A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation

Cytomegalovirus Infections

Primary: Percentage of Participants With Active Cytomegalovirus (CMV) Infection Within 12 Months — 14.1; 42.6 percentage of participants

Hoffmann-La Roche Results Mar 2020 63.6% serious AE View details

Phase 3 N=30 Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone

Opioid Dependence

Primary: Successful Induction Onto XR-NTX — 8 Participants

New York State Psychiatric Institute Results Mar 2020 3.3% serious AE View details

Phase 3 N=25 Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases

Primary Immune Deficiency Disorder

Primary: Number of Serious Bacterial Infections Per Person-Year on Treatment — 0 SBI per patient year

Octapharma Results Mar 2020 0.0% serious AE View details

Phase 3 N=2,104 Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Breast Cancer

Primary: Disease Free Survival — 141; 135; 191; 560 Participants — p=0.0007

NCIC Clinical Trials Group Results Mar 2020 9.4% serious AE View details

Phase 3 N=103 An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

Iron Deficiency Anemia · Iron Deficiency Anaemia

Primary: Number of Subjects With Adverse Drug Reactions (ADR) — 5 Participants

Pharmacosmos A/S Results Mar 2020 12.8% serious AE View details

Phase 3 N=83 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

Thyroid Eye Disease · Graves' Orbitopathy

Primary: Percentage of Participants Who Were Proptosis Responders at Week 24 — 9.5; 82.9 percentage of participants — p=<0.001

Amgen Results Mar 2020 3.6% serious AE View details